Epcoritamab Trial Misses Survival Goal—What It Means for DLBCL Patients

Oncology clinicians managing DLBCL face a rapidly evolving treatment landscape with CAR-T, bispecifics, and antibody-drug conjugates. The news that epcoritamab did not extend overall survival versus chemoimmunotherapy in the EPCORE DLBCL-1 trial will force a re-evaluation of its role in the third-line setting, especially as newer agents with confirmed survival benefits enter the market.

On July 23, 2026, Genmab and AbbVie issued a sobering clarification on the pivotal Phase 3 EPCORE DLBCL-1 trial for epcoritamab, their subcutaneous bispecific antibody targeting CD3 and CD20. The companies revealed that the study missed its sole primary endpoint of overall survival (OS) in the United States, a critical regulatory metric where OS is the gold standard for full approval. This disclosure adds to the topline data presented in January 2026 and at the European Hematology Association Congress in June 2026, but it now explicitly frames the US outcome as a failure. The open-label trial pitted monotherapy epcoritamab against investigator’s choice of chemoimmunotherapy—either R-GemOx or BR—in adults with relapsed/refractory DLBCL ineligible for autologous stem cell transplant. While the drug remains on the market via the FDA’s accelerated approval pathway for third-line DLBCL, this confirmatory trial miss places its full approval in jeopardy and injects significant uncertainty into the drug’s commercial trajectory.

“

Epcoritamab’s accelerated approval was based on response rates in the single-arm EPCORE NHL-1 trial, which showed an overall response rate of 63% and a complete response rate of 39% in heavily pretreated patients.

The regional split in endpoints underscores a strategic complexity: in the US, OS is the sole primary endpoint; in other regions, alternative endpoints like progression-free survival may be acceptable. The companies have not disclosed whether the study met its primary endpoint in non-US regions, leaving room for speculation—and for potential approvals outside the US. However, without a clear OS benefit, the FDA is likely to convene an advisory committee to discuss withdrawal of accelerated approval or demand another confirmatory trial. This puts the onus on the sponsors to generate new evidence, perhaps from ongoing combination studies or longer follow-up, to salvage the indication.

Epcoritamab’s accelerated approval was based on response rates in the single-arm EPCORE NHL-1 trial, which showed an overall response rate of 63% and a complete response rate of 39% in heavily pretreated patients. The drug is co-commercialized in the US and Japan, with AbbVie handling global ex-US markets. Missing the OS endpoint could erode oncologist confidence and slow uptake, especially as competing bispecifics like glofitamab and mosunetuzumab vie for market share. Glofitamab, from Roche, already has full approval for R/R DLBCL after two or more lines based on a randomized trial with an OS benefit, making the epcoritamab setback a competitive vulnerability.

For AbbVie, which has been building an oncology franchise to offset Humira’s biosimilar erosion, epcoritamab was a key pillar. The company reported approximately $300 million in epcoritamab sales in 2025 under accelerated approval. A loss of that indication or a downgraded label could impair revenue growth. Genmab, more reliant on its antibody platform and royalty streams, faces a less direct hit but still notable as epcoritamab is one of its marquee co-developed assets. Both stocks exhibited modest pre-market dips following the clarification, though the news partially priced in after the January topline release.